BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

604 related articles for article (PubMed ID: 25401301)

  • 1. Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes.
    Durinck S; Stawiski EW; Pavía-Jiménez A; Modrusan Z; Kapur P; Jaiswal BS; Zhang N; Toffessi-Tcheuyap V; Nguyen TT; Pahuja KB; Chen YJ; Saleem S; Chaudhuri S; Heldens S; Jackson M; Peña-Llopis S; Guillory J; Toy K; Ha C; Harris CJ; Holloman E; Hill HM; Stinson J; Rivers CS; Janakiraman V; Wang W; Kinch LN; Grishin NV; Haverty PM; Chow B; Gehring JS; Reeder J; Pau G; Wu TD; Margulis V; Lotan Y; Sagalowsky A; Pedrosa I; de Sauvage FJ; Brugarolas J; Seshagiri S
    Nat Genet; 2015 Jan; 47(1):13-21. PubMed ID: 25401301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma.
    Tan MH; Wong CF; Tan HL; Yang XJ; Ditlev J; Matsuda D; Khoo SK; Sugimura J; Fujioka T; Furge KA; Kort E; Giraud S; Ferlicot S; Vielh P; Amsellem-Ouazana D; Debré B; Flam T; Thiounn N; Zerbib M; Benoît G; Droupy S; Molinié V; Vieillefond A; Tan PH; Richard S; Teh BT
    BMC Cancer; 2010 May; 10():196. PubMed ID: 20462447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sporadic oncocytic tumors with features intermediate between oncocytoma and chromophobe renal cell carcinoma: comprehensive clinicopathological and genomic profiling.
    Liu YJ; Ussakli C; Antic T; Liu Y; Wu Y; True L; Tretiakova MS
    Hum Pathol; 2020 Oct; 104():18-29. PubMed ID: 32673684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Messenger RNA expression ratios among four genes predict subtypes of renal cell carcinoma and distinguish oncocytoma from carcinoma.
    Chen YT; Tu JJ; Kao J; Zhou XK; Mazumdar M
    Clin Cancer Res; 2005 Sep; 11(18):6558-66. PubMed ID: 16166433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation.
    Brauch H; Weirich G; Brieger J; Glavac D; Rödl H; Eichinger M; Feurer M; Weidt E; Puranakanitstha C; Neuhaus C; Pomer S; Brenner W; Schirmacher P; Störkel S; Rotter M; Masera A; Gugeler N; Decker HJ
    Cancer Res; 2000 Apr; 60(7):1942-8. PubMed ID: 10766184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel gene fusion of PRCC-MITF defines a new member of MiT family translocation renal cell carcinoma: clinicopathological analysis and detection of the gene fusion by RNA sequencing and FISH.
    Xia QY; Wang XT; Ye SB; Wang X; Li R; Shi SS; Fang R; Zhang RS; Ma HH; Lu ZF; Shen Q; Bao W; Zhou XJ; Rao Q
    Histopathology; 2018 Apr; 72(5):786-794. PubMed ID: 29148086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C-kit expression in renal oncocytomas and chromophobe renal cell carcinomas.
    Huo L; Sugimura J; Tretiakova MS; Patton KT; Gupta R; Popov B; Laskin WB; Yeldandi A; Teh BT; Yang XJ
    Hum Pathol; 2005 Mar; 36(3):262-8. PubMed ID: 15791570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array.
    Albiges L; Guegan J; Le Formal A; Verkarre V; Rioux-Leclercq N; Sibony M; Bernhard JC; Camparo P; Merabet Z; Molinie V; Allory Y; Orear C; Couvé S; Gad S; Patard JJ; Escudier B
    Clin Cancer Res; 2014 Jul; 20(13):3411-21. PubMed ID: 24658158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kidney-specific cadherin correlates with the ontogenetic origin of renal cell carcinoma subtypes: an indicator of a malignant potential?
    Horstmann M; Geiger LM; Vogel U; Schmid H; Hennenlotter J; Kuehs U; Merseburger AS; Kruck S; Stenzl A; Bedke J
    World J Urol; 2012 Aug; 30(4):525-31. PubMed ID: 21928123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Papillary renal cell carcinoma: a clinicopathological and whole-genome exon sequencing study.
    Liu K; Ren Y; Pang L; Qi Y; Jia W; Tao L; Hu Z; Zhao J; Zhang H; Li L; Yue H; Han J; Liang W; Hu J; Zou H; Yuan X; Li F
    Int J Clin Exp Pathol; 2015; 8(7):8311-35. PubMed ID: 26339402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling.
    Pal SK; Ali SM; Yakirevich E; Geynisman DM; Karam JA; Elvin JA; Frampton GM; Huang X; Lin DI; Rosenzweig M; Lipson D; Stephens PJ; Ross JS; Miller VA; Agarwal N; Shuch B; Choueiri TK; Chung JH
    Eur Urol; 2018 Jan; 73(1):71-78. PubMed ID: 28592388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DOG1, cyclin D1, CK7, CD117 and vimentin are useful immunohistochemical markers in distinguishing chromophobe renal cell carcinoma from clear cell renal cell carcinoma and renal oncocytoma.
    Zhao W; Tian B; Wu C; Peng Y; Wang H; Gu WL; Gao FH
    Pathol Res Pract; 2015 Apr; 211(4):303-7. PubMed ID: 25596994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma.
    Ruiz-Cordero R; Rao P; Li L; Qi Y; Atherton D; Peng B; Singh RR; Kim TB; Kawakami F; Routbort MJ; Alouch N; Chow CB; Tang X; Lu W; Brimo F; Matin SF; Wood CG; Tannir NM; Wistuba II; Chen K; Wang J; Medeiros LJ; Karam JA; Tamboli P; Sircar K
    Mod Pathol; 2019 Nov; 32(11):1698-1707. PubMed ID: 31231128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pan-kidney cancer study identifies subtype specific perturbations on pathways with potential drivers in renal cell carcinoma.
    Zhan X; Liu Y; Yu CY; Wang TF; Zhang J; Ni D; Huang K
    BMC Med Genomics; 2020 Dec; 13(Suppl 11):190. PubMed ID: 33371886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential expression of KAI1 metastasis suppressor protein in renal cell tumor histological subtypes.
    Kauffman EC; Barocas DA; Chen YT; Yang XJ; Scherr DS; Tu JJ
    J Urol; 2009 May; 181(5):2305-11. PubMed ID: 19303095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cathepsin K (Clone EPR19992) Demonstrates Uniformly Positive Immunoreactivity in Renal Oncocytoma, Chromophobe Renal Cell Carcinoma, and Distal Tubules.
    Iakymenko OA; Delma KS; Jorda M; Kryvenko ON
    Int J Surg Pathol; 2021 Sep; 29(6):600-605. PubMed ID: 33764165
    [No Abstract]   [Full Text] [Related]  

  • 17. Inactivation of BHD in sporadic renal tumors.
    Khoo SK; Kahnoski K; Sugimura J; Petillo D; Chen J; Shockley K; Ludlow J; Knapp R; Giraud S; Richard S; Nordenskjöld M; Teh BT
    Cancer Res; 2003 Aug; 63(15):4583-7. PubMed ID: 12907635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA methylation profiling distinguishes histological subtypes of renal cell carcinoma.
    Slater AA; Alokail M; Gentle D; Yao M; Kovacs G; Maher ER; Latif F
    Epigenetics; 2013 Mar; 8(3):252-67. PubMed ID: 23428843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors.
    Costa VL; Henrique R; Ribeiro FR; Pinto M; Oliveira J; Lobo F; Teixeira MR; Jerónimo C
    BMC Cancer; 2007 Jul; 7():133. PubMed ID: 17645803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Oncocytoma versus chromophobe renal cell carcinoma: Is there something in between?].
    Lüders C; Kristiansen G
    Pathologe; 2016 Mar; 37(2):153-8. PubMed ID: 26925847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.